Relentless Innovation to Avail Breakthrough Therapies to a Global Community

At XBiotech we are rethinking the way medicines are discovered and commercialized—from pioneering ways to create safer drugs that harness our natural immunity to disease, to developing technology that enables rapid transition from discovery to large-scale manufacturing. At XBiotech we believe there is vast potential for next generation antibody therapies derived from natural immunity to disease. We also believe that to unlock the vast potential of natural immunity to treat escalating global demand for medicine, more cost effective commercialization strategies are needed. To this end, we have developed production technology that is easier to scale-up and more flexible to respond to the rapidly evolving market opportunities, much of which will be created by new safer therapies themselves. At XBiotech we continue to refine and develop systems and strategies to advance our capability to identify antibody therapies from healthy human immunity and avail these to patients in need. In 2015, we believe our innovation in technology and in the clinic enables us to bring our new discoveries to patients faster and with leaner infrastructure than any other biopharmaceutical developer in the industry.


XBiotech Provides Third Quarter 2015 Corporate and Clinical Update

XBiotech Inc. (NASDAQ: XBIT), the world’s leading developer of next-generation True Human™ therapeutic antibodies, today provided a corporate and clinical update for the third quarter ended September 30, 2015. The Company’s CEO and other key members of XBiotech’s management team will provide updates on the company’s clinical, R&D and manufacturing operations...

Press Releases

view all press releases

Clinical Trials

View all current trials

  • Xilonix™ is a first-in-class True Human™ monoclonal (IgG1k) antibody that neutralizes biological activity of interleukin-1&alpha. Xilonix™ is called a True Human™ monoclonal antibody to differentiate it from other antibodies, such as so called "fully human," that are in fact not derived from a mature human antibody sequence...
  • Antibodies are the body's main defense against bacterial infection. Staphylococcus aureus (S. aureus), including methicillin resistant S. aureus (MRSA) strains, however, have specific immune evasion strategies that enable the bacteria to escape neutralization by antibodies...
  • Inflammatory skin conditions encompass a wide range of diagnoses from common conditions such as acne, eczema, and psoriasis, to more rare conditions such as pyoderma gangrenosum. One common factor unifying the pathophysiology of these conditions is...